OS Therapies (OSTX) said Friday it has signed agreements to begin commercial manufacturing of its lead asset OST-HER2 as it prepares for a potential Biologics License Application submission to the US Food and Drug Administration.
The company said it is compiling additional data from its recently completed phase 2b trial of OST-HER2 for lung metastatic osteosarcoma recurrence prevention.
It plans to meet with the FDA for regulatory discussions before submitting a BLA for accelerated or conditional approval, OS Therapies added.
Shares of the company were up more than 36% in recent Friday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.